Obesity is a global epidemic
The global obesity epidemic affects nearly 3 billion people worldwide
In the United States, approximately 42.4% of adults are considered overweight or obese.
Injectable GLP‑1s work — but come at a cost
Current injectable GLP‑1 therapies (such as Ozempic, Wegovy, and Saxenda) are effective but expensive and often come with side effects such as nausea, diarrhea, abdominal pain, and rare but serious adverse events including pancreatitis, kidney injury, and gastroparesis.
GLP‑1 Boosted Probiotic
Our team presents Fleur — an oral delivery system that uses engineered probiotic bacteria to express and secrete wild-type GLP-1 within the gastrointestinal tract, delivered via a yogurt-based drink.
From sip to support
Fleur represents a paradigm shift in peptide therapeutic delivery through synthetic biology:
- 1 Engineered Probiotics: Lactobacillus strains modified to naturally produce GLP‑1 in your gut.
- 2 Targeted Action: GLP‑1 works where it's needed most — right in your digestive system.
- 3 Continuous Support: Living probiotics provide steady, long‑term GLP‑1 production with every serving.
Why Fleur
Fleur aims to combine the therapeutic benefits of GLP‑1 with the natural advantages of probiotics to provide a safer, more affordable, and more accessible option for metabolic health management.
Health should be comforting and accessible
Health innovation shouldn’t come at the cost of comfort, safety, or affordability. Fleur means people everywhere—not just a lucky few—can manage their health with confidence (and a smile).
We Fight For
Accessible, natural, and effective solutions to metabolic disease—developed collaboratively, validated rigorously, and deployed responsibly.
